Compare Procter & Gamble Co (PG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs TG Therapeutics Inc — how do they compare? Procter & Gamble Co trades at $149.52 (market cap $344.87B), while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: Procter & Gamble Co is far larger — about 41.8× TG Therapeutics Inc's market cap, and Procter & Gamble Co pays a 2.94% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| PG | TGTX | |
|---|---|---|
Market Cap | $344.87B | $8.26B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $59.06 |
52-Week Low | $138.10 | $26.39 |
Enterprise Value | $370.34B | $8.50B |
Dividend Yield | 2.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $148.12, down 0.68% on the day, with a neutral technical outlook. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.59 exceeding the $1.56 estimate. Revenue grew to $84.28B in 2025, while net income margin improved to 19.16%. Recent news highlights include a partnership with the WNBA and ongoing supply chain enhancements. The current P/E ratio is 21.65, above industry averages, reflecting premium valuation.
PG offers stable dividend income with a 69-year growth streak, but faces risks from premium valuation and modest revenue growth. Analyst consensus is bullish with a $160.50 price target, suggesting 8% upside. Key risks include economic sensitivity and competitive pressures. The stock remains a core holding for income investors despite near-term volatility.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
